HK Stock MarketDetailed Quotes

01501 INT MEDICAL

Watchlist
  • 27.650
  • 0.0000.00%
Trading Apr 26 10:26 CST
4.87BMarket Cap28.19P/E (TTM)

INT MEDICAL Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

All
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2023
(Q6)Jun 30, 2023
(FY)Dec 31, 2022
(Q6)Jun 30, 2022
(FY)Dec 31, 2021
(Q6)Jun 30, 2021
(FY)Dec 31, 2020
(Q6)Jun 30, 2020
(FY)Dec 31, 2019
(FY)Dec 31, 2018
Turnover
28.50%752.84M
50.86%339.76M
26.08%585.88M
24.70%225.22M
29.64%464.68M
5.10%180.61M
25.12%358.43M
--171.84M
41.07%286.46M
47.62%203.06M
Operating income
28.50%752.84M
50.86%339.76M
26.08%585.88M
24.70%225.22M
29.64%464.68M
5.10%180.61M
25.12%358.43M
171.84M
41.07%286.46M
47.62%203.06M
Cost of sales
-24.22%-314.77M
-37.77%-139.41M
-34.12%-253.4M
-56.46%-101.19M
-52.35%-188.93M
-11.47%-64.68M
-10.71%-124.01M
---58.02M
-32.31%-112.02M
-41.68%-84.66M
Operating expenses
-24.22%-314.77M
-37.77%-139.41M
-34.12%-253.4M
-56.46%-101.19M
-52.35%-188.93M
-11.47%-64.68M
-10.71%-124.01M
-58.02M
-32.31%-112.02M
-41.68%-84.66M
Gross profit
31.76%438.07M
61.54%200.35M
20.58%332.49M
6.98%124.02M
17.63%275.75M
1.86%115.94M
34.38%234.42M
113.82M
47.34%174.44M
52.19%118.4M
Selling expenses
-19.51%-67.4M
-52.00%-33.02M
-87.85%-56.39M
-61.89%-21.72M
-39.79%-30.02M
-5.19%-13.42M
10.37%-21.48M
---12.76M
-36.13%-23.96M
-104.56%-17.6M
Administrative expenses
-54.65%-99.43M
-28.17%-36.39M
-31.07%-64.29M
-37.16%-28.39M
-36.38%-49.05M
-8.48%-20.7M
-5.24%-35.97M
---19.08M
-66.67%-34.18M
-78.47%-20.5M
Research and development expenses
-26.31%-125.85M
-70.30%-64.59M
-10.76%-99.63M
15.83%-37.93M
-39.26%-89.96M
-49.10%-45.06M
-109.96%-64.59M
---30.22M
-39.22%-30.76M
-71.01%-22.1M
Impairment and provision
56.00%-407K
175.51%481K
-63.14%-925K
-2,023.33%-637K
-1,388.64%-567K
-130.77%-30K
109.52%44K
---13K
-81.08%21K
1,287.50%111K
-Other impairment is provision
56.00%-407K
175.51%481K
-63.14%-925K
-2,023.33%-637K
-1,388.64%-567K
-130.77%-30K
109.52%44K
---13K
-81.08%21K
1,287.50%111K
Special items of operating profit
-2.09%33.33M
4.51%22.79M
-32.15%34.04M
-7.00%21.81M
102.70%50.17M
-5.50%23.45M
-12.14%24.75M
--24.82M
190.62%28.17M
229.84%9.69M
Operating profit
22.74%178.32M
56.82%89.62M
-7.06%145.29M
-5.03%57.15M
13.96%156.32M
-21.40%60.18M
20.61%137.18M
76.57M
67.26%113.74M
42.47%68M
Financing cost
-290.46%-3.19M
-274.22%-1.21M
-29.23%-818K
-2.22%-322K
-588.04%-633K
-556.25%-315K
94.96%-92K
---48K
-19.52%-1.83M
---1.53M
Earning before tax
21.22%175.13M
55.58%88.42M
-7.21%144.47M
-5.07%56.83M
13.57%155.69M
-21.77%59.86M
22.49%137.09M
76.52M
68.36%111.91M
39.27%66.47M
Tax
-105.92%-21.9M
-18.02%-7.91M
30.24%-10.64M
21.77%-6.7M
25.88%-15.25M
27.48%-8.57M
-33.75%-20.57M
---11.82M
-86.69%-15.38M
-18.38%-8.24M
After-tax profit from continuing operations
14.49%153.23M
60.61%80.51M
-4.71%133.83M
-2.28%50.13M
20.54%140.45M
-20.72%51.29M
20.70%116.52M
64.7M
65.77%96.54M
42.84%58.24M
Earning after tax
14.49%153.23M
60.61%80.51M
-4.71%133.83M
-2.28%50.13M
20.54%140.45M
-20.72%51.29M
20.70%116.52M
64.7M
65.77%96.54M
42.84%58.24M
Minority profit
-252.31%-3.23M
100.42%3K
184.29%2.12M
-203.92%-716K
48.00%-2.52M
125.59%689K
-57.10%-4.84M
---2.69M
-1,332.09%-3.08M
---215K
Profit attributable to shareholders
18.79%156.46M
58.34%80.5M
-7.87%131.71M
0.47%50.84M
17.80%142.96M
-24.91%50.61M
21.82%121.35M
67.39M
70.42%99.61M
43.37%58.45M
Basic earnings per share
16.46%0.92
54.84%0.48
-8.14%0.79
3.33%0.31
17.81%0.86
-26.83%0.3
-7.59%0.73
0.41
16.18%0.79
38.78%0.68
Diluted earnings per share
17.95%0.92
56.67%0.47
-9.30%0.78
0.00%0.3
17.81%0.86
-26.83%0.3
-7.59%0.73
0.41
16.18%0.79
38.78%0.68
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
Audit Opinions
Unqualified Opinion
--
Unqualified Opinion
--
Unqualified Opinion
--
Unqualified Opinion
--
Unqualified Opinion
Unqualified Opinion
Auditor
KPMG Huazhen Certified Public Accountants (Special General Partnership)
--
Lixin Certified Public Accountants (Special General Partnership)
--
Lixin Certified Public Accountants (Special General Partnership)
--
Lixin Certified Public Accountants (Special General Partnership)
--
Lixin Certified Public Accountants (Special General Partnership)
KPMG
(FY)Dec 31, 2023(Q6)Jun 30, 2023(FY)Dec 31, 2022(Q6)Jun 30, 2022(FY)Dec 31, 2021(Q6)Jun 30, 2021(FY)Dec 31, 2020(Q6)Jun 30, 2020(FY)Dec 31, 2019(FY)Dec 31, 2018
Turnover 28.50%752.84M50.86%339.76M26.08%585.88M24.70%225.22M29.64%464.68M5.10%180.61M25.12%358.43M--171.84M41.07%286.46M47.62%203.06M
Operating income 28.50%752.84M50.86%339.76M26.08%585.88M24.70%225.22M29.64%464.68M5.10%180.61M25.12%358.43M171.84M41.07%286.46M47.62%203.06M
Cost of sales -24.22%-314.77M-37.77%-139.41M-34.12%-253.4M-56.46%-101.19M-52.35%-188.93M-11.47%-64.68M-10.71%-124.01M---58.02M-32.31%-112.02M-41.68%-84.66M
Operating expenses -24.22%-314.77M-37.77%-139.41M-34.12%-253.4M-56.46%-101.19M-52.35%-188.93M-11.47%-64.68M-10.71%-124.01M-58.02M-32.31%-112.02M-41.68%-84.66M
Gross profit 31.76%438.07M61.54%200.35M20.58%332.49M6.98%124.02M17.63%275.75M1.86%115.94M34.38%234.42M113.82M47.34%174.44M52.19%118.4M
Selling expenses -19.51%-67.4M-52.00%-33.02M-87.85%-56.39M-61.89%-21.72M-39.79%-30.02M-5.19%-13.42M10.37%-21.48M---12.76M-36.13%-23.96M-104.56%-17.6M
Administrative expenses -54.65%-99.43M-28.17%-36.39M-31.07%-64.29M-37.16%-28.39M-36.38%-49.05M-8.48%-20.7M-5.24%-35.97M---19.08M-66.67%-34.18M-78.47%-20.5M
Research and development expenses -26.31%-125.85M-70.30%-64.59M-10.76%-99.63M15.83%-37.93M-39.26%-89.96M-49.10%-45.06M-109.96%-64.59M---30.22M-39.22%-30.76M-71.01%-22.1M
Impairment and provision 56.00%-407K175.51%481K-63.14%-925K-2,023.33%-637K-1,388.64%-567K-130.77%-30K109.52%44K---13K-81.08%21K1,287.50%111K
-Other impairment is provision 56.00%-407K175.51%481K-63.14%-925K-2,023.33%-637K-1,388.64%-567K-130.77%-30K109.52%44K---13K-81.08%21K1,287.50%111K
Special items of operating profit -2.09%33.33M4.51%22.79M-32.15%34.04M-7.00%21.81M102.70%50.17M-5.50%23.45M-12.14%24.75M--24.82M190.62%28.17M229.84%9.69M
Operating profit 22.74%178.32M56.82%89.62M-7.06%145.29M-5.03%57.15M13.96%156.32M-21.40%60.18M20.61%137.18M76.57M67.26%113.74M42.47%68M
Financing cost -290.46%-3.19M-274.22%-1.21M-29.23%-818K-2.22%-322K-588.04%-633K-556.25%-315K94.96%-92K---48K-19.52%-1.83M---1.53M
Earning before tax 21.22%175.13M55.58%88.42M-7.21%144.47M-5.07%56.83M13.57%155.69M-21.77%59.86M22.49%137.09M76.52M68.36%111.91M39.27%66.47M
Tax -105.92%-21.9M-18.02%-7.91M30.24%-10.64M21.77%-6.7M25.88%-15.25M27.48%-8.57M-33.75%-20.57M---11.82M-86.69%-15.38M-18.38%-8.24M
After-tax profit from continuing operations 14.49%153.23M60.61%80.51M-4.71%133.83M-2.28%50.13M20.54%140.45M-20.72%51.29M20.70%116.52M64.7M65.77%96.54M42.84%58.24M
Earning after tax 14.49%153.23M60.61%80.51M-4.71%133.83M-2.28%50.13M20.54%140.45M-20.72%51.29M20.70%116.52M64.7M65.77%96.54M42.84%58.24M
Minority profit -252.31%-3.23M100.42%3K184.29%2.12M-203.92%-716K48.00%-2.52M125.59%689K-57.10%-4.84M---2.69M-1,332.09%-3.08M---215K
Profit attributable to shareholders 18.79%156.46M58.34%80.5M-7.87%131.71M0.47%50.84M17.80%142.96M-24.91%50.61M21.82%121.35M67.39M70.42%99.61M43.37%58.45M
Basic earnings per share 16.46%0.9254.84%0.48-8.14%0.793.33%0.3117.81%0.86-26.83%0.3-7.59%0.730.4116.18%0.7938.78%0.68
Diluted earnings per share 17.95%0.9256.67%0.47-9.30%0.780.00%0.317.81%0.86-26.83%0.3-7.59%0.730.4116.18%0.7938.78%0.68
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards HKASHKASHKASHKASHKASHKASHKASHKASHKASHKAS
Audit Opinions Unqualified Opinion--Unqualified Opinion--Unqualified Opinion--Unqualified Opinion--Unqualified OpinionUnqualified Opinion
Auditor KPMG Huazhen Certified Public Accountants (Special General Partnership)--Lixin Certified Public Accountants (Special General Partnership)--Lixin Certified Public Accountants (Special General Partnership)--Lixin Certified Public Accountants (Special General Partnership)--Lixin Certified Public Accountants (Special General Partnership)KPMG

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg